Core Insights - Bionano Genomics, Inc. will have its CEO, Erik Holmlin, participate in the H.C. Wainwright @ Home Event on October 15, 2025 [1][2] Company Overview - Bionano Genomics provides genome analysis solutions aimed at helping researchers and clinicians address complex biological and medical questions [3] - The company's mission is to revolutionize genome visualization through optical genome mapping (OGM) solutions, diagnostic services, and software [3] - Bionano offers OGM solutions applicable in basic, translational, and clinical research, along with a leading platform-agnostic genome analysis software and nucleic acid extraction solutions using proprietary isotachophoresis (ITP) technology [3] - Through its subsidiary, Lineagen, Inc. d/b/a Bionano Laboratories, the company provides OGM-based diagnostic testing services [3]

Core Viewpoint - Bionano Genomics, Inc. has successfully closed a public offering, raising approximately $10 million, with potential additional proceeds of around $20 million from Series Warrants if fully exercised [1][3]. Group 1: Offering Details - The public offering consisted of 5,000,000 shares of common stock and Series E and Series F warrants, all priced at $2.00 per share [1]. - The Series E warrants will expire five years after issuance, while the Series F warrants will expire eighteen months after issuance [1]. - H.C. Wainwright & Co. served as the exclusive placement agent for the offering [2]. Group 2: Financial Implications - The gross proceeds from the offering were approximately $10 million before deducting fees and expenses [3]. - If the Series Warrants are fully exercised, the potential additional gross proceeds could reach approximately $20 million [3]. - The net proceeds from the offering are intended for working capital and general corporate purposes [3]. Group 3: Company Overview - Bionano Genomics provides genome analysis solutions aimed at enhancing research and clinical applications [6]. - The company focuses on optical genome mapping (OGM) solutions and offers diagnostic services and software [6]. - Bionano's mission is to transform genome analysis through innovative technologies, including proprietary isotachophoresis (ITP) [6].

Core Viewpoint - Bionano Genomics, Inc. has announced a public offering of 5,000,000 shares of common stock and associated Series E and Series F warrants, aiming to raise approximately $10 million before expenses, with potential additional proceeds of about $20 million if the warrants are fully exercised [1][3]. Group 1: Offering Details - The public offering price is set at $2.00 per share, with Series E warrants expiring in five years and Series F warrants expiring in eighteen months [1]. - The offering is expected to close on or about September 17, 2025, pending customary closing conditions [1]. - H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering [2]. Group 2: Financial Proceeds - The gross proceeds from the offering are expected to be approximately $10 million before deducting fees and expenses [3]. - If fully exercised, the Series Warrants could provide an additional gross proceeds of approximately $20 million [3]. - The net proceeds will be used for working capital and general corporate purposes [3]. Group 3: Company Overview - Bionano Genomics provides genome analysis solutions aimed at enhancing research and clinical applications [6]. - The company focuses on optical genome mapping (OGM) solutions, diagnostic services, and software, with a mission to transform genome analysis [6]. - Bionano also offers nucleic acid extraction and purification solutions using proprietary isotachophoresis technology [6].

Company Overview - Bionano Genomics, Inc. is a provider of genome analysis solutions aimed at addressing complex questions in biology and medicine [3] - The company's mission is to transform genome visualization through optical genome mapping (OGM) solutions, diagnostic services, and software [3] - Bionano offers OGM solutions applicable in basic, translational, and clinical research, along with a platform-agnostic genome analysis software and nucleic acid extraction solutions using proprietary isotachophoresis (ITP) technology [3] Upcoming Conference - Erik Holmlin, PhD, the CEO of Bionano, will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025 [1] - The presentation is scheduled from 3:00 p.m. to 3:30 p.m. ET [2] - A recording of the session will be available on the Bionano website for at least 30 days following the conference [2]

Core Insights - Bionano Genomics, Inc. announced a peer-reviewed publication demonstrating that optical genome mapping (OGM) is an accurate and cost-effective method for detecting and sizing large repeat expansions linked to 40 genetic disorders [1][3] - The study evaluated 85 subjects with known pathogenic expansions in three genes, providing a comprehensive assessment of OGM's capabilities [1][4] Group 1: Study Findings - OGM identified 84 out of 85 pathogenic repeat expansions, achieving a detection accuracy of 98.8% [7] - OGM measured repeat sizes accurately, even for expansions exceeding 7,000 repeat units, indicating no apparent upper size limit [7] - Evidence of somatic instability was found in 36 out of 85 samples, with variability observed in 30% of DMPK samples, 92% of CNBP samples, and 16% of RFC1 samples [7] Group 2: Methodological Advantages - OGM provides a single technique workflow that detects large repeat expansions across multiple loci, potentially reducing turnaround times and lowering costs compared to traditional methods [4][7] - The study highlights OGM's potential to address long-standing challenges in genome analysis, including structural variation and repeat expansion detection [3][4] Group 3: Company Overview - Bionano is a provider of genome analysis solutions aimed at transforming the understanding of the genome through OGM solutions, diagnostic services, and software [5] - The company offers OGM solutions for various applications in basic, translational, and clinical research, along with industry-leading genome analysis software [5]